BNP Paribas Asset Management
KRYS icon

BNP Paribas Asset Management’s Krystal Biotech KRYS Stock Holding History

BNP Paribas Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
299
-56
-16% -$16.7K ﹤0.01% 1525
2026
Q1 		$91.7K Buy
355
+93
+35% +$24.7K ﹤0.01% 1530
2025
Q4 		$65K Buy
262
+88
+51% +$18.5K ﹤0.01% 1585
2025
Q3 		$31K Hold
174
– – ﹤0.01% 1225
2025
Q2 		$24K Buy
+174
New +$25.6K ﹤0.01% 1428

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BNP Paribas Asset Management's KRYS Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Krystal Biotech (KRYS) stake by 16% in Q2 2026, selling an estimated $16.7K and leaving 299 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

BNP Paribas Asset Management first reported a position in KRYS in Q2 2025 and has held it in 5 quarters since. 330 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • BNP Paribas Asset Management held 299 shares of Krystal Biotech worth $111K as of Q2 2026.
  • BNP Paribas Asset Management sold 56 Krystal Biotech shares in Q2 2026, an estimated $16.7K.
  • Krystal Biotech made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1525 holding.
  • BNP Paribas Asset Management first reported a position in Krystal Biotech in Q2 2025 and has held it in 5 quarters since.
  • 330 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.